Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients (NCT01057888) | Clinical Trial Compass
CompletedNot Applicable
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
10,599 participantsStarted 2009-12
Plain-language summary
The investigators will design and implement a randomized clinical trial to test, on a community-wide level, the effectiveness of managed care based tracking/reminder/recall on improving vaccination coverage among adolescents.
The investigators propose a randomized controlled trial to evaluate the effectiveness of reminder/recall for adolescents: 10,599 adolescents within the managed care organization (MCO) will be randomized into one of three arms: 1) mailed reminders, 2) autodialer telephone messages or 3) standard of care of their practice (no messages from the intervention).
Hypothesis 1: Reminder/recall will increase the receipt of immunizations and preventive services
Hypothesis 2: Telephone (autodialer) reminders will be more effective than mailed reminders
Hypothesis 3: The impact of reminders will be greatest for the most high-risk subgroups which have low baseline immunization rates.
Hypothesis 4: Mailed reminders will be more costly (and less effective) than telephone reminders.
Who can participate
Age range
11 Years – 18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Member of the Monroe Plan for Medical Care (managed care organization)
* Patient of a participating practice
* Ages 10.75 to \<18 years of age
Exclusion Criteria:
* Member of the Monroe Plan for Medical care for less than 6 months
* ICD-9 diagnosis of 999.4 for anaphylactic reaction to a vaccine or its components.
* Encephalopathy within 7 days of a previous dose of a pertussis containing vaccine not attributable to another identifiable cause
* Guillain-Barre- ICD-9 code is 357.0
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Fully Vaccinated (Tdap, Menactra and 3 Doses of HPV (if Female))